Abstract It is many years since the general population has been vaccinated against smallpox virus. Here, we report that human leukocyte antigen (HLA) class I restricted T cell epitopes can be recognized more than 30 years after vaccination. Using bioinformatic methods, we predicted 177 potential cytotoxic T lymphocyte epitopes. Eight epitopes were confirmed to stimulate IFN-c release by T cells in smallpox-vaccinated subjects. The epitopes were restricted by five supertypes (HLA-A1, -A2, -A24 -A26 and -B44). Significant T cell responses were detected against 8 of 45 peptides with an HLA class I affinity of K D less than or equal to 5 nM, whereas no T cell responses were detected against 60 peptides with an HLA affinity of K D more than 5 nM. All epitopes were fully conserved in seven variola, vaccinia and cowpox strains. Knowledge of the long-term response to smallpox vaccination may lead to a better understanding of poxvirus immunity and may aid in the development of new improved vaccines and diagnostic tools.
Introduction
Despite the great success of smallpox vaccination, surprisingly, little knowledge exists of how vaccination induces protection. It has been shown that vaccination with VACV antigens induces antibody responses that contribute to protective immunity against VARV and generate both memory T and B cells that remain more than 50 years after vaccination [13, 20] despite the absence of smallpox. Neutralizing antibodies appear to be important for protection in a mouse model [14] , and the neutralizing antibody titers are correlated with anti-vaccinia antibodies [13, 36] . In recent years it has become increasingly clear that cellular immunity can also play an important role in protection against smallpox. Protection against orthopoxvirus challenge can be obtained after immunisation with single CD8? T cell epitopes [41] . Most of the CTL responses described are observed shortly after vaccination, but longterm central memory responses associated with CD8? T cells as well as CD4? T cells have also been reported [10] . CD8? T lymphocytes have been shown to be involved in controlling poxvirus infection, and this has prompted a search for potential CD8? T cell epitopes [16, 27, 28, 31, 33, 35, 41, [45] [46] [47] . In recent years, over 150 T cell epitopes from human and mouse have been identified (reviewed by Kennedy and Poland [22] ). Orthopoxviruses encode multiple classes of immunomodulatory proteins that interfere with various aspects of the host innate and adaptive immune system [1, 5, 8, 9, 11, 12, 15, 21, 23, 30, 34, 38, 44] . The objective of this study was to find novel CTL S. T. Tang and M. Wang contributed equally to this work.
NetCTL epitope prediction
The NetCTL prediction method [24] was used for predicting 9mer pox CTL epitopes for the entire genome of VARV-IND. Prediction was performed for 12 HLA supertypes [25] : A1, A2, A3, A24, A26, B7, B8, B27, B39, B44, B58, and B62. This provides a broad coverage ([99%) of the HLA alleles worldwide. The 9mer peptides were sorted based on the NetCTL score, which is a combined score for MHC binding, TAP binding and proteasomal cleavage. A threshold cut-off value of 0.42 in NetMHC, corresponding to a predicted binding affinity of better than 500 nM, was used.
Identification of ortholog proteins
A computer program, ''Genediff'', was developed in order to find the orthologous proteins among the different selected orthopox strains. The Genediff program generated a list of conserved proteins that were shared among all seven selected orthopox virus strains. The program uses Blast [2] to find the most similar protein to each protein in the reference strain in another strain with the restriction that the Blast E-value has to be lower than 0.05. In this way, each of the strains are compared to the reference strain. These results were combined to identify 157 proteins found in all strains.
Selection of epitopes in immunomodulatory proteins
The whole genome of VACV-COP (a total of 262 open reading frames) was scanned in order to find viral immunomodulatory proteins. By using a bioinformatic server, ProtFun (http://www.cbs.dtu.dk/services/), finding orthologs to other known vaccinia virus proteins (http://www. pox.org) and literature search in PubMed at NCBI, 58 potential immunomodulators were found in VACV-COP. Twenty-two of these were found to be among the 157 orthologous proteins conserved among the seven orthopoxvirus strains included in this study. We predicted epitopes in these 22 immunomodulatory proteins and filtered out the 9-mers that were not found in all seven strains, giving 93 selected peptides from 16 different potential immunomodulators.
Selection of conserved epitopes that were identical in all seven strains of orthopox viruses Conserved predicted CTL epitopes were selected among the list of remaining orthologs after the immunomodulatory proteins had been picked. These 96 peptides are distributed in 47 different proteins.
Finding ''self peptides''
When comparing the entire human genome with VACV-COP using Genediff, 54 orthologs were found. Only one predicted epitope, RVYNNTARY, was found to be identical to a human self peptide, and this was kept in this study.
Selection of a known CD8? T cell epitope
Twelve known pox CTL epitopes were found at the initiation of this study (This number has since increased to more than 150 human epitopes against vaccinia virus [22] . Two of these epitopes, CLTEYILWV (NP_042046.1, gene: D1L) and KVDDTFYYV (NP_042052.1, gene: D8L), were tested on 3 A*0201-positive donors. One known epitope, SLSAYIIRV (NP_042130.1, gene: I3L), was selected to be synthesized.
Collection of blood samples
Buffy coats of 500 ml whole blood from 35 healthy Danish donors (age range: 35-65 years with a sex ratio of 51% female and 49% male; donors had given written informed consent) were obtained from The Blood Bank at Rigshospitalet (Copenhagen, Denmark) and used within 24 h to isolate peripheral blood mononuclear cells (PBMC). The donors were selected according to serological typing of their HLA-A and -B haplotype to maximize coverage of the 12 HLA class I supertypes. A high-resolution sequence-based typing (SBT) of the HLA-A and HLA-B loci was subsequently established (Genome Diagnostics, Utrecht, the Netherlands). Data for donors are shown in Table 1 . The number of peptides tested in each donor was variable due to the different HLA supertypes of the donors. All of the HLA-matched donors among the cohort of 35 donors were used for testing a peptide restricted by the same HLA supertype as that of the donors. On the average, 33 peptides (range: 7-47) were tested in each donor.
Isolation of PBMCs
PBMCs were isolated from buffy coats by density gradient centrifugation using Lymphoprep (Nycomed Pharma AS, Oslo, Norway). The freshly isolated PBMCs were cryopreserved for later use at a concentration of 20 9 10 6 cells in 1 ml RPMI-1640 containing 20% FCS and 10% dimethyl sulfoxide (DMSO) at -140°C.
Peptides
The 9mer peptides were synthesized by standard 9-fluorenylmethyloxycarbonyl (FMOC) chemistry, purified by reversed-phase high-performance liquid chromatography (at least 80%, usually [95% purity) and validated by mass spectrometry (Shafer-N, Copenhagen, Denmark). Peptides were distributed at 500 lg/vial and stored lyophilized at -20°C until use. Peptides were dissolved just before use.
Biochemical peptide-HLA class I binding assay
The biochemical assay for peptide-MHC-I binding was performed as described previously [42, 43] . Briefly, denatured and purified recombinant HLA heavy chains were diluted in a renaturation buffer containing HLA heavy chain, b 2 -microglobulin, and graded concentrations of the test peptide, and incubated at 18°C for 48 h, allowing equilibrium to be reached. We have previously demonstrated that denatured HLA molecules can fold efficiently de novo, but only in the presence of an appropriate peptide [32] . The concentration of the peptide-HLA complexes generated was measured in a quantitative enzyme-linked immunosorbent assay and plotted against the concentration of peptide used [42] . Because the effective concentration of HLA (3-5 nM) used in these assays is below the equilibrium dissociation constant (K D ) of most high-affinity peptide-HLA interactions, the peptide concentration leading to half-saturation of the HLA is a reasonable approximation of the affinity of the interaction. An initial screening procedure was employed in which a single high concentration (20,000 nM) of peptide was tested. If no complex formation was found, the peptide was assigned as a non-binder to the HLA molecule in question; conversely, if complex formation was found in the initial screening, a full titration of the peptide was performed to determine the affinity of binding.
IFN-c ELISPOT assay
PBMCs were thawed, washed and resuspended at a concentration of 6-8 9 10
6 cells per ml in RPMI-1640 supplemented with 5% heat-inactivated AB serum (Valley Biomedical, Winchester, USA), 2 mM L-glutamine, 100 U/ml penicillin and 100 lg/ml streptomycin. Cells were cultured in 24-well plates (Nunc, Roskilde, Denmark). Individual peptides were added to a final concentration of 20 lg/ml per well and incubated for 10 days at 37°C, 5% CO 2 in humidified air. RhIL-2 (Proleukin; Chiron, The Netherlands), 20 U/ml, was added on day 1. Cells were harvested on day 10, washed twice in RPMI-1640 and resuspended in complete medium to a final concentration of 1 9 10 6 cells/ml. The IFN-c ELISPOT assay was performed as described previously [49] to quantify peptidespecific CD8? T cells after in vitro expansion. Briefly, 96-well ELISPOT plates (Multiscreen, MAHAS4510; Millipore, Molsheim, France) were coated overnight at 4°C with 7.5 lg/ml anti-human IFN-c (M-700A, Endogen; Pierce Biotechnology, Rockford, IL, USA). The plates were washed six times with sterile phosphate-buffered saline (PBS) to remove unbound coating antibody. Cell suspensions were prepared, and six replicate wells were seeded with 10 5 cells per well. Peptides were added to a final concentration of 10 lg/ml. As positive controls, cells were stimulated with 10 lg/ml phytohaemaglutinin (PHA) (Sigma-Aldrich, UK). Cells were incubated with complete medium alone as a negative control. After incubation for 18-20 h at 37°C and 5% CO 2 , plates were washed with PBS containing 0.05% Tween-20. Biotinylated anti-human IFN-c (M-701B, Endogen; Pierce Biotechnology, Rockford, IL, USA) was added at 0.75 lg/ml, and plates were incubated for 2 h at room temperature. After incubation, plates were washed and incubated further for 1 h with streptavidin-conjugated peroxidase (Dako, Copenhagen, Denmark) diluted 1:500 in PBS/1% BSA. Next, the plates were washed as before, and 200 ll of substrate [30 mg 4-chloro-1-naphthol (057h8927, Sigma) dissolved in 10 ml methanol, diluted in 50 ml triethanol-buffered H 2 O (T1377, Sigma) at pH 7.5 and 25 ll H 2 O 2 30% (H1009, Sigma)] was added to the wells. Finally, plates were washed under running tap water and dried at room temperature. IFN-c spot-forming cells (SFC) were counted using an ELISPOT reader (KS ELISpot, Zeiss, Munich, 
Statistics
A Wilcoxon rank-sum test was used to analyze the quantitative differences between the experimental wells and the control in ELISPOT assays. A P value below 0.05 was considered significant.
Results
Computational prediction of peptides binding to MHC class I molecules from the vaccinia virus genome that are 100% conserved in related orthopox viruses
In this study, artificial neural networks (ANNs) were used to predict vaccinia virus CTL epitopes. We have developed an algorithm program, Genediff, in order to find all of the orthologous proteins that are shared among seven strains of related orthopoxviruses. Vaccinia virus strain Copenhagen, with 262 ORFs, was chosen to be our reference strain because this strain was used as the vaccine strain for the Danish donor cohort included in this study. The orthologous proteins were found in the following orthopox viruses: variola virus strain India-1967 (VARV-IND), variola virus strain Bangladesh (VARV-BSH), vaccinia virus strain Acambis 3000 Modified Virus Ankara (VACV-MVA), vaccinia virus strain Western Reserve (VACV-WR), cowpox virus strain Brighton Red (CPV-BR) and cowpox virus strain GRI-90 (CPV-GRI-90). One hundred fifty-seven orthologs were found to be shared among the seven selected strains; these were divided into two groups. The first group consists of 22 potential immunomodulators that were present in all seven strains, while the second group contains the remaining conserved orthologous proteins. Since pox viruses in general have many immunomodulatory proteins, we investigated whether human T cells were able to target peptides within these proteins. The web server NetCTL was used for in silico CTL epitope prediction [24] . For each supertype, we synthesized up to 20 peptides with the highest NetCTL scores that had NetMHC scores of at least 0.42 and were found to be 100% conserved in all seven fully sequenced orthopoxvirus strains. Due to difficulties with the synthesis, some of the predicted peptides were discarded. Thus, at the end, we tested 86 out of 93 selected predicted peptides originating from 16 of the immunomodulators and 91 out of 96 predicted peptides from 46 of the conserved proteins.
Confirmation of MHC-I binding of predicted epitopes
A total of 177 peptides were synthesized and tested in a biochemical in vitro binding assay [42, 43] Table 2 ). In this study, 139 out of 177 measured peptides (79%) bound to their respective HLA molecules with a K D B 500 nM.
Eight VACV-COP epitopes elicited IFN-c release in ELISPOT assays
The peptides were evaluated for their ability to stimulate IFN-c production in an ELISPOT assay by PBMC from an individual donor vaccinated more than 30 years ago with VACV. In order to increase the low frequency of peptidespecific T cells, PBMC were exposed for 10 days to peptides prior to performing the ELISPOT assays. A total of 105 HLA class I-binding peptides were assayed for IFN-c ELISPOT formation. Immunogenicity was observed for eight out of 45 peptides that bound with a K D B 5 nM. None of 60 tested peptides with an affinity [5 nM induced a response. This correlation of affinity and immunogenicity is highly significant (P \ 0.001, two-tailed, Fischer exact test).
Eight positive peptides belonging to five different supertypes (A1, A2, A24, A26 and B44) were found to elicit a significant (P \ 0.05) immune response in at least one donor in two independent experiments. These responses ranged from 8-208 IFN-c spots per 10 5 PBMCs. All of the significant ELISPOT data are listed in Table 3 , and a donor-specific overview is given in Table 1 . In order to verify that these T cell responses were restricted by MHC class I molecules, anti-MHC class I antibody W6/32 was added in IFN-c ELISPOT assays for the identified epitopes.
The anti-MHC class I antibody was found to block peptideinduced IFN-c release (data not shown), which together with the peptide-MHC binding data support that the epitope-induced responses are MHC class I restricted. Table 4 shows the reactivity of each of the donors against each of the peptides. Each peptide was only tested in donors that had at least one allele within the supertype by which the peptide was predicted to be restricted. Individual donor immunity was only directed against a few of the peptides shown in the table, and not against several peptides, as would have been the case if all reactivity was generated during the in vitro culture. These data thus suggest that the responses were generated from pre-existing immunity in the donors. None of the eight peptides have been found in non-poxviruses, suggesting that this immunity must have been elicited by the pox vaccinations. Six epitopes were recognized by more than one donor (Table 3) . One peptide (N1L 70 _RMIAISAKV (A2) was recognized by four different HLA-A2 ? donors (donors 13, 19, 30 and 31) and five peptides were recognized by two different donors with matched HLA supertype. The last two epitopes were only recognized by one donor.
One donor (donor 19) exhibited a broad response against half of the identified epitopes (4 out of 8), three of these were HLA-A2 restricted (E1L 212 _FLIDLAFLI, A42R 73 _ LMDENTYAM and N1L 70 _RMIAISAKV) and one was B44 restricted (H1L 47 _ SEVKFKYVL). In total, 11 donors responded to at least one peptide (Table 1) . The actual number of peptides tested for each group of binders in IFN-c ELISPOT assay is shown in parentheses in boldface type In bold, peptide tested negative in other studies Nature of the antigens recognized in VACV-COP
The eight epitopes were derived from eight different VACV-COP proteins (A10L, A18R, A20R, E1L, A38L, A42R, H1L and N1L). 
Discussion
In this article, we have identified eight VACV-COP MHC I restricted T cell epitopes. The epitopes were selected so that they would be 100% conserved among VARV-IND, VARV-BSH, VACV-MVA, and VACV-WR as well as in two other orthopoxviruses, the cowpox virus strains CPV-BR and CPV-GRI-90. The identified epitopes are restricted by HLA-A1, -A2, -A24, -A26 and -B44. To our knowledge, the epitope A38L 256 VSEHFSLLF has not been studied before. Seven of the epitopes identified in the present study were reported to be non-immunogenic in previous studies (http://www.immuneepitope.org/). Such differences can be expected, since each subject responds to different sets of peptides, and testing a peptide in more subjects increases the chance that it is recognized as an epitope in at least one subject.
The subjects in our study cohort were healthy Danish blood bank donors with an age range from 35 to 62 years. Most Danes were vaccinated more than 30 years ago with the vaccinia virus vaccine strain Copenhagen. Only one study has examined epitope recognition in long-term vaccinia virus vaccinees without re-vaccination [33] . Ostrout and colleagues tested 46 HLA-A2-restricted peptides and found a positive IFN-c response towards 6 of these [33] . In the present study, we have screened peptides from 11 different HLA supertypes that have been calculated to have an average population coverage of more than 99% [39] . The experimental setup of Ostrout differs from ours in that they did not expand the donor PBMC in vitro before performing their ELISPOT assay, but instead used a longer incubation time for the ELISPOT assay (42 h instead of 18-20 h in the present study). Ostrout et al. included both non-A2 vaccinees and a group of HLA-A2 donors who were never vaccinated. The age range of the latter group was not provided, but we believe that these donors must have been below 27-30 years of age. We decided not to include such a control group, since these donors are younger than the group that have been exposed to poxvirus and therefore may not be an appropriate control group. The present study is the first to describe epitope specific T cell responses restricted to HLA-A1, -A24, -A26 and -B44 supertypes in long-term vaccinia virus vaccinees without re-vaccination. Most of the other studies involving pox epitope recognition have used T cells from donors re-vaccinated with vaccinia vaccine [31] , established VACV-specific CTL lines [46] , or used inbred mice expressing mouse alleles (K b or D b ) [28, 48] or transgenic mice expressing human HLA molecules [35] . The T cell responses detected in the present study can be expected to be long-term T cell memory responses. The data in Table 4 strongly support the conclusion that spots are formed by in vivo peptide-specific preexisting cells and not by peptide-specific cells generated in the in vitro culture. The argument goes as such: The five HLA-A1-or A2-binding peptides in the table are immunogenic, but reactivity is only present in 9 of 28 different HLA-1 or A-2 matched donors. Thus, if immune reactivity was only generated in vitro, all five immunogenic peptides should have induced formation of spots in the 9 immune HLA-A1 or -A2 donors. Apparently, this is not the case. Thus, immune reactivity against pox peptides must have already existed in vivo.
A total of 31% of the donors (11 out of 35 donors) responded to one or more of the eight identified epitopes. The responders were on the average older than the nonresponders, but this difference was not significant (P = 0.18, paired, two-tailed Student t test). In our study, we showed that long-term memory T cells directed towards vaccinia and variola epitopes persist in humans in the complete absence of original antigens. A previous study indicated that vaccination gave 90% protection against lethal smallpox infection for more than 20 years [26] . CD4? T cells have been shown to be the principal component of long-term cellular memory to VACV [3, 20] . Hammerlund et al. (2003) studied the duration of antiviral immunity after smallpox vaccination [20] . They found that detectable antiviral CD8? T cell memory was maintained in only *50% of the vaccinees 20 years after the last vaccination, regardless of how many booster vaccinations these individuals had received. These authors question whether CD8? T cell memory is required for protection and conclude that CD4? T cell memory or neutralizing antibody responses (or both) may constitute the main components of long-term immunity against smallpox after CD8? T cell memory has faded. The study by Combadiere et al. showed that in vitro stimulation increased the frequency of effector memory cells producing IFN-c, and their study indicated that both CD4? and CD8? T cells are involved in VACV-specific memory responses. According to Combadiere et al., T cell effector memory vanished, but T cell proliferative memory persisted or stabilized. The latter remained stable, independent of the time since priming with [70% responses. Anti-vaccinia proliferative T cell responses were shown to be maintained many years after antigen exposure, while T cell effector memory/central memory was shown to vanish 45 years after the first vaccination [10] .
Many studies focus on genes that are expressed at the early stages of infection as, due to their relatively abundant expression, the proteins may be more available for the host immune system [28, 29, 31, 46] . Here, we identified three epitopes in three late gene products (A10L, E1L and A42R); two were expressed early (A20R and A38L) and three were found to be expressed both early and late (A18R, H1L and N1L). From these data, we cannot observe any bias towards early-expressed gene products being preferentially targeted by T cells. The 21 CD8? restricted T cell epitopes found by Pasquetto et al. were also primarily from late-expressed genes [35] .
It can be expected that the number of epitopes hosted by a protein should be proportional to the length of the protein. Oseroff et al. [31] studied the protein size differences in proteins with and without epitopes. They studied approximately 6,000 peptides and observed that all 48 of the identified positive epitopes were contained in relatively large proteins ([100 residues), whereas no epitopes were found in small proteins (\100 residues). All of our positive epitopes were from proteins with[100 residues and appear to support the findings of Oseroff et al. In this study, we found four epitopes in each of the two groups of proteins: the group of conserved and the group of immunomodulatory proteins. Thus, in our study, the function of a protein does not appear to be of importance for immunogenicity. Many epitopes have been discovered in the meantime by other groups, and these are found to be distributed over all functional classes of vaccinia virus proteins [22] . Previously, we showed that most influenza CTL epitopes found among peptides that bind to a HLA molecule bind with K D B 500 nM [49] . This is in agreement with a previous review [50] in which it was stated that 500 nM is the HLA binding affinity threshold for immunogenicity. Here, we show that pox CTL epitopes, more than 30 years after immunization, are exclusively found among peptides binding with an affinity of B5 nM, suggesting that longterm memory is associated with high peptide-HLA binding affinities.
In conclusion, we have identified a total of eight T cell epitopes. This investigation confirmed that bioinformatic analysis can facilitate the discovery of epitopes with a broad conservation in a fast and efficient way. This may be used in the design of a future improved vaccine or of a diagnostic tool for smallpox.
